Pregnancy
How NIPT has evolved and what AI NIPT means in 2026
Article produced in association with London Pregnancy Clinic and Spital Clinic
Non-invasive prenatal testing has been part of antenatal care in the UK since the early 2010s.
In the years since its introduction, the test has undergone significant expansion in terms of what it can detect, how early it can be performed, and how its results are interpreted.
In 2026, NIPT is also beginning to incorporate artificial intelligence at the analysis stage.
This article explains what the test currently involves, what has changed, and what the phrase ‘AI NIPT’ actually refers to in clinical practice.
How Non-Invasive Prenatal Testing Works
From around nine weeks of pregnancy, small fragments of fetal DNA circulate in the maternal bloodstream. These are known as cell-free fetal DNA (cffDNA).
NIPT works by extracting this DNA from a maternal blood sample and analysing it to detect chromosomal differences in the fetus.
Because the test uses a maternal blood draw rather than sampling the placenta or amniotic fluid, it carries no risk of miscarriage.
It is a screening test rather than a diagnostic one, meaning a positive result requires confirmation through a diagnostic procedure such as CVS or amniocentesis.
NICE guidance on non-invasive prenatal testing, published as Diagnostics Guidance DG46, sets out the evidence for its use in detecting the three most common trisomies.
Currently, the NHS does not offer Non-Invasive Prenatal Testing (NIPT) to all pregnant individuals, but rather as a contingent or second-line test for a select group deemed at higher chance of carrying a baby with certain chromosomal conditions
What NIPT Can Now Detect
When NIPT was introduced, tests typically screened for trisomies 21, 18 and 13. Detection capabilities have expanded considerably since then.
Tests available in 2026 can screen for:
- All chromosomal trisomies and some monosomies across the 23 pairs of chromosomes
- Sex chromosome conditions including Turner syndrome (45,X) and Klinefelter syndrome (47,XXY)
- Microdeletions: small missing sections of chromosomes associated with conditions such as DiGeorge syndrome, Angelman syndrome and Prader-Willi syndrome
- Single-gene disorders, where parental carrier status has been established
Tests such as the KNOVA NIPT, for which London Pregnancy Clinic was the first UK provider, are now capable of screening for up to 100 conditions from a single blood draw.
This represents a substantial expansion from the three-trisomy scope of a decade ago.
What Has Changed in 2026
Three developments characterise the current state of NIPT in clinical practice.
First, testing is available earlier, with reliable results from nine weeks and some protocols beginning comprehensive genomic assessment from 10 weeks.
Second, expanded condition panels mean that families can choose the level of detection most appropriate for their situation, from basic trisomy screening to comprehensive genomic analysis.
Third, integrated prenatal pathways are becoming more common, combining NIPT with detailed anatomical scanning and genetics counselling rather than treating the test as a standalone investigation.
What AI NIPT Means in Practice
Artificial intelligence has entered NIPT analysis at the stage where raw cfDNA data is processed and interpreted.
Traditional NIPT analysis uses statistical models to compare the proportions of chromosomal DNA fragments in the maternal sample. AI-enhanced platforms apply machine learning to this process.
A study published in Frontiers in Genetics describes the development of an algorithm using cfDNA fragment distance analysis that improves accuracy by modelling the data in a more nuanced way than conventional statistical approaches.
In clinical practice, the most established AI NIPT platform is Panorama AI NIPT, which applies machine learning to cell-free DNA analysis to improve sensitivity and specificity for common aneuploidies and to extend detection to rarer variants.
The term ‘AI NIPT’ describes this category of platform, not a single product, and it is expected to become standard across major NIPT providers as the underlying technology matures.
The key clinical difference between AI-powered and conventional NIPT is not the type of conditions screened for but the quality of the analysis applied to the same data.
This translates to fewer false positives, fewer uninformative results and greater confidence in a negative finding.
Choosing Between Available Tests
The choice of NIPT should be guided by individual clinical circumstances and pre-test genetic counselling. For families with no known genetic risk factors, standard trisomy screening provides high accuracy at lower cost.
For those with a family history of genetic conditions or who have received an abnormal ultrasound finding, an extended panel or AI-powered test may be appropriate.
The Importance of Genetic Counselling
NIPT is a screening test and, like all screening tests, it produces a probability rather than a certainty. A positive result requires follow-up diagnostic testing before any clinical decisions are made.
A negative result substantially reduces risk but does not eliminate it. Understanding what results mean in both directions requires expert clinical input.
Pre-test counselling ensures that patients understand what they are consenting to; post-test counselling ensures that results are interpreted accurately and next steps are clear.
This is particularly important for expanded panels, where the clinical significance of some findings may be uncertain or variable in presentation.
Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment.
Clinical guidance referenced reflects published NHS, NICE and RCOG standards as at March 2026. Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article.
This piece was produced in association with London Pregnancy Clinic and Spital Clinic, which provided background clinical information for editorial purposes.
Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.
Early miscarriage care after a first loss could prevent about 10,000 pregnancy losses a year in the UK, according to a new study.
The study by Tommy’s National Centre for Miscarriage Research and Birmingham women’s hospital involving 406 women found a 4 per cent reduction in the risk of future miscarriage for women on the graded model of care compared with usual care.
Women in England, Wales and Northern Ireland currently become eligible for specialised NHS care for early baby loss only after they have had at least three miscarriages.
Tommy’s has called for women to become eligible after one miscarriage, saying this could reduce the risk of future miscarriages and improve health outcomes for mothers.
Researchers said that would translate to 10,075 fewer miscarriages a year across the UK.
Kath Abrahams, chief executive of Tommy’s, said women were being “left without early access to services that could help prevent future losses and reduce the debilitating feelings of isolation and hopelessness that we know affect so many who experience pregnancy loss”.
She said: “Our pilot study indicates that providing support after a first miscarriage, with escalating care after further losses, is not only effective but achievable without significant additional workload for NHS teams who are already working extremely hard to deliver good care.
“Put simply, it is the right thing to do. We will do all we can to drive that change across the UK so that more women and families are supported after every miscarriage.”
The graded model of miscarriage care proposed by Tommy’s is already available in Scotland, and the charity is calling for it to be introduced across the whole of the UK.
The graded model includes nurse-led support after one miscarriage, with advice on reducing risk factors such as low vitamin D, folic acid intake, alcohol consumption and caffeine use.
Women who received the specialised care were 47 per cent more likely to have a risk factor identified and receive relevant advice to help prevent future miscarriages than women receiving usual care, the study found.
Among women who had experienced two miscarriages and received the specialised care, one in five were found to have thyroid dysfunction or anaemia, both conditions that can affect pregnancy outcomes.
About one in four pregnancies ends in miscarriage, most often within the first 12 weeks of pregnancy.
The report comes ahead of the long-awaited final findings of the government’s investigation into maternity care in England. Interim findings uncovered a range of failures, including claims that NHS hospitals that caused harm to women and babies during childbirth often resorted to a “cover-up” of their mistakes, falsified medical records and denied bereaved parents answers.
Women’s health minister Gillian Merron said: “Pregnancy and baby loss can have a devastating impact on women and families, who too often feel they have been left without the care and support they need.
“I welcome the findings of this important report, and this will be carefully considered as part of our ongoing work to make sure women get the high-quality, compassionate NHS care they deserve.”
Home blood pressure checks after hypertensive pregnancy could cut the risk of heart attack, stroke and potentially early death, research suggests.
Women who regularly monitored their blood pressure in the weeks after giving birth, and had doctors tailor their medication if needed, had better functioning arteries nine months later than those who received routine care.
When the medication was adjusted to account for blood pressure changes, the women ended up with less stiff arteries, an effect researchers estimated could reduce the future risk of heart attack or stroke by 10 per cent.
Paul Leeson, professor of cardiovascular medicine who led the study, said the findings suggested that the weeks after birth provided a “powerful and often overlooked opportunity” to protect women’s future health.
“By simply monitoring blood pressure at home, new mothers with hypertensive pregnancies can protect their bodies from future damage,” he said.
High blood pressure, in the form of gestational hypertension or pre-eclampsia, where there are signs of organ damage, affects 5 to 10 per cent of pregnant women.
The condition can damage the mother’s organs and endanger the baby’s life.
Beyond the immediate threat to mother and baby, hypertension in pregnancy can raise the risk of long-term problems, with women three times more likely to develop high blood pressure and twice as likely to have heart disease later in life.
The Oxford team recruited 220 women who developed hypertension in pregnancy. All were on blood pressure medication but were due to reduce their dosage and eventually stop taking the drugs.
In the study, 108 women had standard care in which their medication was reduced based on a few blood pressure checks in the eight weeks after giving birth.
The remaining 112 women used a monitor to check their blood pressure at home each day.
They entered the readings into an app shared with doctors who, if needed, changed their medication day to day, with the aim of giving them better control of their blood pressure.
The new approach led to much better control of the women’s blood pressure, and in tests six to nine months later the women had less stiff arteries.
Stiff arteries are less effective at expanding and contracting, which can drive high blood pressure and ultimately the formation of clots that can block blood vessels and cause heart attacks and strokes.
Trials are now under way to find effective ways of rolling out blood pressure monitoring to women after hypertensive pregnancies. One option is for specialist NHS clinics to deliver the care.
Dr Sonya Babu-Narayan, clinical director at the British Heart Foundation, which funded the work, said the results highlighted a crucial window after birth when paying close attention to blood pressure could help protect women’s heart health for years to come.
“We now look forward to seeing results from larger studies with longer follow-up to see how this might save women’s lives,” she said.
More than half of women with gestational diabetes report stigma from healthcare staff, family, friends and wider society, new research shows.
A survey of 1,800 UK women found widespread emotional distress at diagnosis of the condition, a form of high blood sugar that develops during pregnancy, with effects lasting beyond birth.
Gestational diabetes affects around one in 20 pregnancies in the UK, and the findings highlight the wider toll on women diagnosed with the condition.
The study was funded by Diabetes UK and led by researchers at King’s College London and University College Cork.
Dr Elizabeth Robertson, director of research and clinical at Diabetes UK, said: “Stigma can have a dangerous and devastating impact on pregnant women diagnosed with gestational diabetes, particularly at a time when emotions and anxieties may already be heightened.
“We know that stigma can lead to shame, isolation and poorer mental health, and may discourage people from attending healthcare appointments, potentially increasing the risk of serious complications.
“This research highlights the urgent need for better support systems, based on understanding and empathy to ensure no one feels blamed or judged during their pregnancy.”
More than two-thirds of women, 68 per cent, reported anxiety at diagnosis, while 58 per cent felt upset and 48 per cent experienced fear.
The psychological impact continued beyond birth, with 61 per cent saying the condition negatively affected their feelings about future pregnancies.
Nearly half of women, 49 per cent, felt judged for having gestational diabetes, while 47 per cent felt judged because of their body size.
More than 80 per cent felt other people did not understand gestational diabetes, and more than a third, 36 per cent, concealed their diagnosis from others.
Gestational diabetes stigma was also common in healthcare settings, with 48 per cent reporting that professionals made assumptions about their diet and exercise, and more than half, 52 per cent, feeling judged based on their blood glucose results.
Many women described a loss of control and a sense of disruption during pregnancy.
Nearly two-thirds, 64 per cent, felt they were denied a normal pregnancy, while 76 per cent reported a lack of control over their pregnancy.
More than a third, 36 per cent, felt abandoned by healthcare services after giving birth, and one in four, 25 per cent, continued to experience depression or anxiety postpartum.
Focus group participants described harmful stereotypes, including assumptions that they were ‘lazy’, had ‘poor eating habits’ or ‘lacked willpower’.
Comments from family and friends included remarks such as “should you be eating that?” and “you must have eaten too much, that’s why you have gestational diabetes.”
The researchers are calling for targeted interventions alongside structured emotional support for women during and after pregnancies affected by gestational diabetes, to improve both mental and physical health outcomes.
Professor Angus Forbes, lead researcher from King’s College London, said: “Stigma and emotional distress are far more common in women diagnosed with gestational diabetes than many realise.
“Everyday interactions, even with those who mean well, can deepen this harm, shaping women’s emotional wellbeing and the choices they feel able to make.
“It’s clear that meaningful action is needed to protect women’s mental and physical health.”
Risk factors for gestational diabetes include living with overweight or obesity, having a family history of type 2 diabetes, and being from a South Asian, Black or African Caribbean or Middle Eastern background.
Entrepreneur6 days agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Entrepreneur4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Diagnosis2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Mental health1 week agoLifting weights shows mental health and cognitive benefits in older women, study finds
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says
News4 weeks agoCopper coil vs Mirena: Which is right for you?
News3 weeks agoSelf-employment linked to better cardiovascular health outcomes in Hispanic women